Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously performed a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Jayappa, Kallesh D., Portell, Craig A., Gordon, Vicki L., Capaldo, Brian J., Bekiranov, Stefan, Axelrod, Mark J., Brett, L. Kyle, Wulfkuhle, Julia D., Gallagher, Rosa I., Petricoin, Emanuel F., Bender, Timothy P., Williams, Michael E., Weber, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637393/
https://ncbi.nlm.nih.gov/pubmed/29034364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016004176
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados